For patients with acute coronary syndrome undergoing percutaneous coronary intervention, treatment with dual antiplatelet therapy (DAPT) is standard of care. Proton pump inhibitor (PPI) medications reduce the risk of gastrointestinal (GI) bleeding in patients who require antiplatelet therapy. Current guidelines recommend primary prophylaxis with PPI in patients on DAPT with 1 or more of the following: history of upper GI bleeding; advanced age; concurrent use of anticoagulants, steroids, or nonsteroidal anti-inflammatory drugs; or active Helicobacter pylori infection.